SAB Biotherapeutics IncSABS
Price$3.06

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income $13.3MTTM through 31 Mar 2026
Free Cash Flow -$53.2MTTM through 31 Mar 2026

Margins

Current
Gross Margin0.0%

Returns

-32.0%ROE
-25.4%ROA

Balance Sheet Health

Debt / Equity0.03x
Current Ratio11.45x
Net Debt-$101.2Mnet cash position
Cash & Equivalents$20.5M

Quality Metrics

Earnings-Beat Rate33.3%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Immunotherapeutic Polyclonal Antibodies$0
View details

Enrollment is on track to complete by the end of 2026, with topline data expected in the second half of 2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.